SUMMARY-The Mantoux response was evaluated in 2 groups of patients with carcinoma. In 47 patients with primary carcinoma of the gastrointestinal tract, breast, and prostate, the Mantoux responses were depressed before primary tumor resection, compared with 25 patients tested after resection and with 62 normal controls. Fifty-nine patients with bronchial carcinoma had normal or stronger reactions than controls.
of cellmediated immunity, as shown by the Mantoux reaction, described a diminished response in cancer patients. Results have been similar but do not coincide. Hughes and Mackay (1) considered that in general all patients with carcinoma had diminished tuberculin responses, but Lamb et al. (2) concluded that patients with early carcinoma had normal Mantoux responses which became increasingly negative with disease spread. These investigations have expressed the Mantoux as negative or positive and have placed all types of cancer together.
To investigate these differences, an evaluation of the Mantoux response was undertaken in two population groups.
MATERIALS AND METHODS
Old Tuberculin (Evans) I :1000 was used initially in Ireland. In later studies in an English population, purified protein derivative (PPD) I :5000 was used. Results were similar; 0.1 rnl was injected intradermally in the flexor aspect of the forearm, and the induration recorded at 48, 72, and 96 hours. These values were essentially similar, in agreement with (1) , and the 72-hour value was noted.
Series i.-Forty consecutive patients admitted to a general hospital with suspected cancer and twenty-four with non-STEWARD malignant disease of gastrointestinal tract (GIT), breast, and prostate were Mantoux tested. Of the former group, 22 were found to be free of malignancy and formed a suitable control which could be compared with the intended control formed by the second group. Only patients with primary cancer, confirmed by investigation and surgery, were included in this series. Cancer and control patients were retested, either postoperatively (3 weeks after the initial test) or after investigation and medical treatment and, as available, again 6-8 weeks later. Additionally, 16 consecutive follow-up patients were tested who had previous resection of GIT (10) or breast cancer (4) and were cancer free, and 2 patients who had previous estrogen treatment for prostate carcinoma.
To test relevance of population and area selection in the results, a further series of patients with colon carcinoma, and control patients investigated for cancer but disease-free, was repeated in England.
Two patients with breast cancer (Cii, table I) had previously had irradiation. Otherwise, none received immunosuppressive drugs or irradiation during the investigation.
Series 2.-Fifty-nine consecutive patients with carcinoma of the bronchus were similarly tested with Old Tuberculin I: 1000, together with eighteen patients with nonmalignant and non tuberculous thoracic conditions. Twenty-four patients with carcinoma had surgical resection of the tumor. They were retested after surgery at 9-14 days. Eighteen patients with nonmalignant and nontuberculous disease were tested: Twelve had major surgery (esophagectomy, hiatus hernia repair, decortication, lobectomy) and were retested before leaving the hospital. This study was also done in Ireland.
Series 3.-The ability of serum of carcinoma patients to inhibit lymphocyte transformation to tuberculin in culture was investigated with the use of partially purified lymphocytes prepared by the method of Coulson and Chalmers (3). Triplicate cultures containing 2 million lymphocytes from a Mantoux-positive healthy subject were set up in 2 cc Eagle's medium with 12% autologous serum; I p,g PPD (Protoderm Glaxo) was added to each culture. To a control triplicate no further serum addition was made, but to test triplicates 0.1 ml homologous cancer patient serum was added. Further controls were formed by the use of 0.1 ml homologous normal pooled serum. Lymphocyte proliferation was assessed by the incorporation of thymidine into DNA 96 hours after initiation of culture: 2 p,Ci 3H-thymidine (6-T-thymidine, Radiochemical Centre, Amersham, England) was added for I hour, and the uptake counted by the trichloroacetic acid precipitation technique (4) .
Suppressive effect of cancer patient serum was shown by the thymidine uptake of the test cultures, expressed as a percentage of uptake in control cultures to which no other serum addition had been made.
RESULTS

Series 1
Patients investigated for cancer and found to be malignancy-free had a Mantoux spread similar to that of the control group admitted for the treatment of benign diseases (table 1) .
Patients with primary cancer of the colon, rectum, prostate, and breast in the Irish population had significantly depressed (P<O.OOl) Mantoux responses compared with patients who had had treatment of these neoplasms (tables 1, 2). Decreased responses in patients with primary colon and rectal tumors, compared with controls, was also seen in the English population (table 2). None of the 42 patients with colon cancer had a history of tuberculosis.
Of 9 patients whose course and Mantoux were followed from before to after treatment, 8 showed a detectable increase in their Mantoux response: 4 
C. 34 consecutive patients with carcinoma of the gastrointestinal tract, breast, and prostate seen either before or after treatment i) 18 consecutive patients with carcinoma of the gastrointestinal tract (12), breast (4), and prostate (2), seen before treatmenk _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ 2. 1 ± 1. 6 ii) * 16 consecutive patients with carcinoma of the gastrointestinal tract (10) , breast (4), and prostate (2), seen after treatment** ______________________ 20. 8±3. 6
-Group-ii patieuts uot the same patieuts as in group i. (table 5) .
Series 2
Fifty-nine patients with bronchial cancer had a Mantoux result spread before treatment which was not depressed when compared with their control group or to the control group of the previous investigation (table 2) . They were at least as strong as their controls and appeared stronger. The intensity of preoperative Mantoux response was not influenced by weight loss or age of the patient (text- fig. 1 ), but correlated with tumor differentiation: 14 of 21 patients with undifferentiated tumors had reactions greater than 10 mm, compared with 5 of 14 patients with differentiated tumors (table 6) .
Of the 59 patients, 6 had previously confirmed tuberculous disease (5 pulmonary infections and 1 cervical node infection). Of 37 patients undergoing thoracotomy for bronchial cancer, 16 had a clear en 
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Series 3
The transformation of normal Mantoux-positive lymphocytes to tuberculin was suppressed by the serum of 7 of 8 patients with carcinoma of the colon and rectum, 1 of 2 with carcinoma of the stomach, 1 of 2 with carcinoma of the bronchus, and 2 of 4 with carcinoma of the breast (table 7) .
A dose-response curve of the serum effect showed suppression by addition of 0.1-0.001 ml serum to a 2-ml culture (5-0.05%). It was not complement dependent and also withstood heating at 56° C for 30 minutes. With addition of 0.0001 ml, no suppression occurred, and a small stimulatory effect on DNA synthesis appeared (table 8 ).
In 2 patients tested before and after surgery, suppression diminished; this indicated a dilution effect after removal of the tumor. Another patient who had a by-pass operation, leaving tumor in situ, had a continuous suppressive effect to her serum (text- fig. 3 ).
DISCUSSION
Previous investigations of the tuberculin response in carcinoma grouped together patients with all types of the disease and expressed results as negative or degrees of positivity (1, 2) . had depressed responses, and patients with bronchial carcinoma had responses which were not depressed; they were at least as strong as their control and appeared stronger. A survey of mixed cases might have shown an overall normal response (2), or a depressed one (1) if the emphasis was on gastrointestinal and breast cancer. Investigators reporting results as negative or degree of positive would be unlikely to pick up changes in Mantoux sensitivity, especially if measurements were by different observers.
Hughes and Mackay (1) reported that of 13 patients with carcinoma (site unspecified) who were Mantoux negative before operation, 9 had died within 18 months, whereas only 2 of 7 Mantoux-positive patients did so. The present study showed that, although patients with bronchial cancer had a poor prognosis, they had tuberculin sensitivity similar to, or stronger than, controls. Patients with gastrointestinal cancer usually died in Mantoux negativity; patients with bronchial cancer usually died in positivity. Differences in response between pre-resection and post-resection groups may have been due either to "selecting out" patients with negative Mantoux by perioperative mortality, or to a change in patient response after primary tumor resection. An increase in the Mantoux response occurred 2-6 weeks after resection of colonic and rectal cancer m 6 of 7 patients, and within 10 days of bronchial tumor resection in 16 of 24 patients. Such a change in response was not seen in the control patients tested, but was also found in 2 patients with prostatic carcinoma who received intravenous estrogen therapy (table 4) . Tuberculin test results in these patients before their illness were not known, but because this increase in Mantoux occurred spontaneously, was not associated with BeG injection, and was not seen in control patients (table 3) , it appeared to be a "release" of sensitivity already present but suppressed in the presence of the tumor, rather than a "conversion" from a preexisting negativity to positivity. Mantoux enhancement did not necessarily indicate curative surgery, nor did a strong Mantoux necessarily indicate a good prognosis. Patients died with local and distant spread and yet had a strong Mantoux. Mantoux release implied a change in immunologic status occurring after treatment directed against solid tumors, but not necessarily indicating a favorable host response. Post-treatment groups had responses which were also stronger than control groups. The reason for this is unclear. Natural selection of patients may have played a part; lymphostimulation by a circulating factor may also have been responsible (see below).
A circulating factor has been reported responsible for Mantoux negativity in sarcoid and miliary tuberculosis before suitable in vitro systems were available: When injected intradermally with tuberculin into control subjects, patient sera diminished the skin response (5, 6) . In this series a factor which could suppress the DNA synthesis of tuberculin-stimulated lymphocytes was found in the serum of 7 of 8 Mantoux-negative patients with carcinoma of the colon, in 2 of 4 with carcinoma of the breast, and I of 2 with bronchial carcinoma. In these last 6 cases of breast and bronchus, the 3 patients whose sera were Iymphosuppressive had "negative" Mantoux, and the other 3 were Mantoux "positive." Those patients whose sera contained Iymphosuppressive factor showed Mantoux release after tumor resection.
The tuberculin response is a complex phenomenon, and conditions influencing it have been summarized (7, 8) . Fluctuating Iymphosuppressive levels may be only one cause of a changing Mantoux response. Age and weight loss have been considered to affect the Mantoux, but did not relate to the bronchial carcinoma patients in this study (text- fig. 1 ), although colon cancer patients are usually older and have lost weight. Previous observations that repeated skin testing on the same site may change skin sensitivity have not agreed (9, 10) . In the present study, absence of change in the controls, together with choice of a different skin site for repeat testing, excluded this possibility. Thymusdependent lymphocytes are the sensitized cells which respond to tuberculin, and a change in circulating levels may have contributed to Mantoux release. Transfer of sensitized lymphocytes by blood transfusion, however, was not a likely cause: Banked blood was given to most control patients as well as to the tumor patients.
Serum inhibition of phytohemagglutinin (PHA) responses in a proportion of patients with carcinoma has been described (11) . It was suggested that antibody against alloantigens of the fetus present in the sera of healthy female multi-gravida could suppress PHA responses of normal lymphocytes. Blood transfusion may also produce such alloantibodies. In the present series of II patients showing suppressive activity, 9 were female and 2 were male; 4 patients (2 female, 2 male) had no history of either pregnancy or blood transfusion. Of 5 patients with no suppression, 3 were female and 2 were male.
VOL. 50, NO.3, MARCH 1973 Serum inhibitory activities of alpha2-ribonuclease and -globulin have been described (4, 12, 13) . The technique to demonstrate suppression in the present study was that used to assay inhibitory alpha2-ribonuclease, but there is no evidence that the two substances are the same, though neither is complement dependent and both resist heating to 56° C for 30 minutes. Dose-response studies showed that lymphocyte transformation to tuberculin was suppressed by the cancer serum in higher concentrations and mildly stimulated in lower ones (lOOO-fold range of dilution). This far tor therefore may have an ambivalent quality, being either lymphosuppressive or lymphostimulatory, depending on concentration. Alternatively, more than one factor may be present which are concentration dependent [termed Iymphosuppressive-stimulatory factor(s) (LSSF)]. Such biphasic effect is a characteristic of antibody (14, 15) , and antibody interacting with the lymphocyte must be considered as a possible cause of the su ppression.
On the other hand, two patients with colonic carcinoma had a decrease in their serum lymphosuppressive effect within a week of tumor resection (giving way to a lymphostimulation in one), whereas another patient who underwent by-pass operation, with the neoplasm left in situ, showed continued suppression (text- fig. 3 ). Serum suppression may therefore be a result of tumor secretion or of tumor-host-interaction.
LSSF was best demonstrated in Mantouxnegative patients with colonic carcinoma who underwent Mantoux release 2-6 weeks after tumor resection. However, 16 of 24 patients with bronchial carcinoma, whose Mantoux reactions were not apparently suppressed when compared with a control group, also showed Mantoux release within 2 weeks of cancer resection. Possibly, low concentrations of this factor were circulating in these patients in a concentration sufficient to cause only mild Iymphosuppression. Mantoux enhancement after tumor resection may have been due to further clearance from the circula tion.
In the experimental animal, suppression of host cellular-immune response has been shown during tumor induction with the chemical carcinogen 3-methylcholanthrene (16) , after exposure to the Gross tumor virus (17) , and in mice with spontaneous mammary carcinoma (18) . It is nonspecific (i.e., not specifically related to tumor antigens), as shown by the prolonged survival of coexisting skin allografts (18) . Serum inhibitors of lymphocyte responses appear to have a similar nonspecific property; the possibility of a more specific role cannot be ruled out at this stage.
